SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Wyeth And Progenics Pharmaceuticals, Inc. Initiate Second Global Phase 3 Trial Of Intravenous Methylnaltrexone To Treat Post-operative Ileus